Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 2Thoracic 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Melanoma 67Skin Neoplasms 15Neoplasm Metastasis 14Lymphoma, T-Cell, Cutaneous 9Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 8Breast Neoplasms 8Neoplasms 7Lymphoma 7Ovarian Neoplasms 6Mycosis Fungoides 6Kidney Neoplasms 6Colorectal Neoplasms 6Carcinoma, Merkel Cell 6Uterine Cervical Neoplasms 5Sezary Syndrome 5Multiple Myeloma 5Esophageal Neoplasms 5Carcinoma, Hepatocellular 5Uveal Melanoma 4Stomach Neoplasms 4Sarcoma, Synovial 4Pancreatic Neoplasms 4Lung Neoplasms 4Head and Neck Neoplasms 4Urinary Bladder Neoplasms 3Triple Negative Breast Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Neuroblastoma 3Lymphoma, Non-Hodgkin 3

Interventions

fludarabine phosphate 1fludarabine 1entinostat 1carboxyamido-triazole 1aldesleukin 1Thalidomide 1Paclitaxel 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Meningioma × fludarabine × Dermatologic × Clear all
NCT01967823 2021-03-24

T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
11 enrolled 12 charts
BreastCNSDermatologicGastrointestinalThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Meningioma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡